A screen for and validation of prodrug antimicrobials

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1410-1419

  Fleck, Laura E ^a   North, E Jeffrey ^b   Lee, Richard E ^b   Mulcahy, Lawrence R ^a   Casadei, Gabriele ^c   Lewis, Kim ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLA LOMBARDIA E DELL EMILIA ROMAGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIKETONE; ADC 111; ADC 112; ADC 113; ANTIINFECTIVE AGENT; CIPROFLOXACIN; DYE; NITROFURAN; NITROFURANTOIN; NITROREDUCTASE; PRODRUG; TILBROQUINOL; TILIQUINOL; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BIOFILM; CELL CULTURE; CELL KILLING; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENTEROCOCCUS FAECALIS; FRANCISELLA TULARENSIS; NONHUMAN; PRIORITY JOURNAL; RESAZURIN ASSAY; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION;

ANTI-INFECTIVE AGENTS; BACTERIA; BACTERIAL INFECTIONS; BIOFILMS; DRUG EVALUATION, PRECLINICAL; ESCHERICHIA COLI; PRODRUGS;

EID: 84896880099     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02136-13     Document Type: Article

References (49)

1. Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI. 2011. Tackling antibiotic resistance. Nat. Rev. Microbiol. 9:894-896. http://dx.doi.org/10.1038/nrmicro2693.
2. Lewis K. 2010. Persister cells. Annu. Rev. Microbiol. 64:357-372. http://dx.doi.org/10.1146/annurev.micro.112408.134306.
3. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322. http://dx.doi.org/10.1126/science.284.5418.1318. (Pubitemid 29289651)
4. Keren I, Shah D, Spoering A, Kaldalu N, Lewis K. 2004. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J. Bacteriol. 186:8172-8180. http://dx.doi.org/10.1128/JB.186.24.8172-8180.2004. (Pubitemid 39603206)
5. Maisonneuve E, Shakespeare LJ, Jorgensen MG, Gerdes K. 2011. Bacterial persistence by RNA endonucleases. Proc. Natl. Acad. Sci. U. S. A. 108:13206-13211. http://dx.doi.org/10.1073/pnas.1100186108.
6. Schumacher MA, Piro KM, Xu W, Hansen S, Lewis K, Brennan RG. 2009. Molecular mechanisms of HipA-mediated multidrug tolerance and its neutralization by HipB. Science 323:396-401. http://dx.doi.org/10.1126/science.1163806.
7. Dorr T, Vulić M, Lewis K. 2010. Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol. 8:e1000317. http: //dx.doi.org/10.1371/journal.pbio.1000317.
8. Keren I, Wu Y, Inocencio J, Mulcahy LR, Lewis K. 2013. Killing by bactericidal antibiotics does not depend on reactive oxygen species. Science 339:1213-1216. http://dx.doi.org/10.1126/science.1232688.
9. Hooper DC. 2001. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin. Infect. Dis. 15:S9-S15.
10. Lomovskaya O, Lewis K. 1992. Emr, an Escherichia coli locus for multidrug resistance. Proc. Natl. Acad. Sci. U. S. A. 89:8938-8942. http://dx.doi.org/10. 1073/pnas.89.19.8938.
11. Li XZ, Nikaido H. 2004. Efflux-mediated drug resistance in bacteria. Drugs 64:159-204. http://dx.doi.org/10.2165/00003495-200464020-00004. (Pubitemid 38186964)
12. Lewis K. 2013. Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 12:371-387. http://dx.doi.org/10.1038/nrd3975.
13. Hilliard JJ, Goldschmidt RM, Licata L, Baum EZ, Bush K. 1999. Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems. Antimicrob. Agents Chemother. 43: 1693-1699. (Pubitemid 29331249)
14. Miller JH. 1992. A short course in bacterial genetics: a laboratory manual and handbook for Escherichia coli and related bacteria. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
15. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. 2006. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2:2006.0008. http://dx.doi.org/10.1038/msb4100050.
16. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U. S. A. 97:6640-6645. http://dx.doi.org/10.1073/pnas.120163297. (Pubitemid 30412767)
17. Lutz R, Bujard H. 1997. Independent and tight regulation of transcriptional units in Escherichia coli via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements. Nucleic Acids Res. 25:1203-1210. http://dx.doi.org/10.1093/nar/25.6.1203. (Pubitemid 27303212)
18. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K (ed). 1987. Current protocols in microbiology. John Wiley & Sons, Inc., New York, NY.
19. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K (ed). 1992. Short protocols in microbiology, 2nd ed. John Wiley & Sons, Inc., New York, NY.
20. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: a laboratory manual. Cold Spring Laboratory Press, Cold Spring Harbor, NY.
21. Zhang JH, Chung TD, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:67-73. http://dx.doi.org/10.1177/108705719900400206. (Pubitemid 29278954)
22. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-ninth edition. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
23. Clinical and Laboratory Standards Institute. 2012. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standardeighth edition. CLSI document M11-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
24. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. 1999. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 37:1771-1776. (Pubitemid 29235221)
25. Guay DR. 2001. An update on the role of nitrofurans in the management of urinary tract infections. Drugs 61:353-364. http://dx.doi.org/10.2165/00003495- 200161030-00004. (Pubitemid 32270044)
26. Bryskier A (ed). 2005. Antimicrobial agents: antibacterials and antifungals. ASM Press, Washington, DC.
27. Gershon H, Parmegiani R. 1963. Antimicrobial activity of 8-quinolinol, its salts with salicylic acid and 3-hydroxy-2-naphthoic acid, and the respective copper (II) chelates in liquid culture. Appl. Microbiol. 11:62-65.
28. Okusu H, Ma D, Nikaido H. 1996. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic- resistance (Mar) mutants. J. Bacteriol. 178:306-308. (Pubitemid 26006095)
29. Tegos G, Stermitz FR, Lomovskaya O, Lewis K. 2002. Multidrug pump inhibitors uncover remarkable activity of plant antimicrobials. Antimicrob. Agents Chemother. 46:3133-3141. http://dx.doi.org/10.1128/AAC.46.10.3133-3141. 2002.
30. McCalla DR, Kaiser C, Green MH. 1978. Genetics of nitrofurazone resistance in Escherichia coli. J. Bacteriol. 133:10-16. (Pubitemid 8259417)
31. Whiteway J, Koziarz P, Veall J, Sandhu N, Kumar P, Hoecher B, Lambert IB. 1998. Oxygen-insensitive nitroreductases: analysis of the roles of nfsA and nfsB in development of resistance to 5-nitrofuran derivatives in Escherichia coli. J. Bacteriol. 180:5529-5539. (Pubitemid 28489842)
32. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. 2003. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301:105-107. http://dx.doi.org/10.1126/science.1084550. (Pubitemid 36801572)
33. Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. 2004. Persister cells and tolerance to antimicrobials. FEMS Microbiol. Lett. 230:13-18. http://dx.doi.org/10.1016/S0378-1097(03)00856-5. (Pubitemid 38091733)
34. Spoering AL, Lewis K. 2001. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J. Bacteriol. 183:6746-6751. http://dx.doi.org/10.1128/JB.183.23.6746-6751.2001. (Pubitemid 33064186)
35. Gilbert DN. 2006. Urinary tract infections in patients with chronic renal insufficiency. Clin. J. Am. Soc. Nephrol. 1:327-331. http://dx.doi.org/10.2215/ CJN.01931105.
36. Lewin CS, Morrissey I, Smith JT. 1991. The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment. Eur. J. Clin. Microbiol. Infect. Dis. 10:240-248. http://dx.doi.org/10.1007/BF01966996.
37. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6:29-40. http://dx.doi.org/10.1038/nrd2201. (Pubitemid 46020284)
38. Lewis K. 2012. Antibiotics: recover the lost art of drug discovery. Nature 485:439-440. http://dx.doi.org/10.1038/485439a.
39. Miyamoto Y, Kalisiak J, Korthals K, Lauwaet T, Cheung DY, Lozano R, Cobo ER, Upcroft P, Upcroft JA, Berg DE, Gillin FD, Fokin VV, Sharpless KB, Eckmann L. 2013. Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity. Proc. Natl. Acad. Sci. U. S. A. 110:17564-17569. http://dx.doi.org/10.1073/pnas.1302664110.
40. Lewis K. 2007. Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol. 5:48-56. http://dx.doi.org/10.1038/nrmicro1557. (Pubitemid 44942303)
41. Alekshun MN, Levy SB. 2007. Molecular mechanisms of antibacterial multidrug resistance. Cell 128:1037-1050. http://dx.doi.org/10.1016/j.cell.2007. 03.004. (Pubitemid 46427883)
42. Edwards DI. 1993. Nitroimidazole drugs-action and resistance mechanisms I. Mechanism of action. J. Antimicrob. Chemother. 31:9-20. http://dx.doi.org/10. 1093/jac/31.1.9. (Pubitemid 23078062)
43. Müller M. 1986. Reductive activation of nitroimidazoles in anaerobic microorganisms. Biochem. Pharmacol. 35:37-41. http://dx.doi.org/10.1016/0006- 2952(86)90552-6. (Pubitemid 16161360)
44. Shah RR, Wade G. 1989. Reappraisal of the risk/benefit of nitrofurantoin: review of toxicity and efficacy. Adverse Drug React. Acute Poisoning Rev. 8:183-201. (Pubitemid 20065817)
45. Bhowruth V, Brown AK, Besra GS. 2008. Synthesis and biological evaluation of NAS-21 and NAS-91 analogues as potential inhibitors of the mycobacterial FAS-II dehydratase enzyme Rv0636. Microbiology 154: 1866-1875. http://dx.doi.org/10.1099/mic.0.2008/017434-0.
46. Mysorekar IU, Hultgren SJ. 2006. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc. Natl. Acad. Sci. U. S. A. 103:14170-14175. http://dx.doi.org/10.1073/pnas.0602136103. (Pubitemid 44452998)
47. Schilling JD, Hultgren SJ. 2002. Recent advances into the pathogenesis of recurrent urinary tract infections: the bladder as a reservoir for uropathogenic Escherichia coli. Int. J. Antimicrob. Agents 19:457-460. http://dx.doi.org/10.1016/S0924-8579(02)00098-5. (Pubitemid 34835681)
48. Silverman JA, Schreiber HL, IV, Hooton TM, Hultgren SJ. 2013. From physiology to pharmacy: developments in the pathogenesis and treatment of recurrent urinary tract infections. Curr. Urol. Rep. 14:448-456. http://dx.doi.org/10.1007/s11934-013-0354-5.
49. Conlon BP, Nakayasu ES, Fleck LE, Lafleur MD, Isabella VM, Coleman K, Leonard SN, Smith RD, Adkins JN, Lewis K. 2013. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 503:365- 370. http://dx.doi.org/10.1038/nature12790.